Ascendis Pharma Maps 2026 U.S. Launch of Once-Weekly YUVIWEL After FDA Approval in Achondroplasia

Key Points

• FDA approval of YUVIWEL (navepegritide) establishes the first once-weekly TransCon CNP prodrug for pediatric achondroplasia, with pivotal ApproaCH data showing a statistically significant increase in annualized growth velocity of 1.5 cm/year versus placebo (LS mean 5.9 vs 4.4 cm/year; p<0.0001).
• Ascendis expects U.S. commercial availability in early Q2 2026, plans a premium pricing approach (price to be announced imminently), and will support access through copay assistance, reimbursement support, and patient affordability programs that could reduce out‑of‑pocket costs to as little as $0/month for eligible commercially insured patients.
• The company was granted a Rare Pediatric Disease Priority Review Voucher likely to be sold, estimates a U.S. pediatric achondroplasia population of ~2,600 (≈30% currently treated), and is pursuing EU approval by end‑2026 plus additional studies for infants, adults, and other indications.

Ascendis Pharma A/S NASDAQ: ASND executives outlined plans for the U.S. launch of YUVIWEL following FDA approval, describing the product as the first once-weekly treatment for children with achondroplasia and emphasizing its label, clinical profile, and expected near-term commercialization steps.

FDA approval details and clinical basis

Chief Executive Officer Jan Mikkelsen said the FDA approval of YUVIWEL marks the company’s third FDA-approved drug. Management stated that the approval was based on data from three randomized, double-blind, placebo-controlled trials, including the pivotal ApproaCH trial.

Chief Medical Officer Amy Xu reviewed efficacy data from ApproaCH, stating that superiority versus placebo was demonstrated for the primary endpoint of annualized growth velocity (AGV) at week 52. She said children treated with navepegritide achieved an LS mean AGV of 5.9 cm/year versus 4.4 cm/year for placebo, for an LS mean treatment difference of 1.5 cm/year (confidence interval 1.0–1.9; p<0.0001). Xu added that AGV increased across age subgroups, including a 1.8 cm/year treatment difference in participants aged five years and older. She also said treatment benefits were observed for both achondroplasia-specific and CDC-based height Z-scores, with a treatment difference of 0.3 for change from baseline.

Mechanism and label highlights emphasized by management

Mikkelsen and Xu described YUVIWEL as a TransCon technology-enabled prodrug of C-type natriuretic peptide (CNP) designed to provide continuous exposure with controlled release. Xu said the carrier component extends circulation time via a shielding effect, with the CNP moiety inactive while bound and released in a controlled manner, which she said is intended to maintain a low peak-to-trough profile and avoid high peak concentrations associated with natriuretic or low blood pressure effects.

Executives highlighted several elements from the U.S. prescribing information, including:

• Indication: to increase linear growth in pediatric patients aged two years and older.
• Dosing: once-weekly subcutaneous injection with dosing based on body weight, with periodic monitoring and dose adjustment.
• Discontinuation: when no further growth potential is seen, as indicated by epiphyseal closure.
• Switch guidance: start once-weekly YUVIWEL the day after the last dose of daily CNP therapy.
• Storage: can be stored at room temperature up to 86°F for up to six months and returned to refrigeration within that period if desired.

In response to investor questions about injection site reactions versus daily CNP therapy, Mikkelsen attributed differences to TransCon technology, describing the injected product as “inactive” at the injection site and saying the released peptide is liberated after diffusion into the blood compartment, which he said was part of the design to improve tolerability.

Commercial launch timing, access strategy, and pricing updates

Jay Wu, EVP and President of the U.S. market, said Ascendis is prepared to support commercial availability in the early part of the second quarter of 2026. Mikkelsen explained that launch is not immediate because final FDA-approved packaging and insert details must be incorporated, requiring time for printing and packaging.

Wu said Ascendis has engaged with advocacy groups since 2017 and plans to support education with centers of excellence, thought leaders, and patient groups, alongside multichannel outreach to patients and caregivers. He also described the company’s Ascendis Signature Access Program, which includes reimbursement support, out-of-pocket assistance, and training resources. Wu said the company anticipates eligible commercially insured patients will pay as little as $0 per month with a copay card, and that government payer patients and uninsured or underinsured patients would be supported through affordability programs and screening for assistance.

On pricing, Mikkelsen said Ascendis had not disclosed a price as of the call but expects a premium pricing strategy aligned with the product’s clinical value proposition. Wu added that the company expects to make the price public “either later this week or potentially even next.”

Market opportunity and 2026 milestones

Wu said Ascendis estimates the U.S. pediatric achondroplasia population at approximately 2,600, with about 30% currently on pharmacological treatment. He described multiple patient segments, including those on daily therapy, those who previously discontinued therapy, and those who have never used pharmacological treatment. Wu said the company expects uptake to come from both switch patients and treatment-naïve patients, citing interest since approval from patients asking about switching and commercial availability.

Mikkelsen outlined 2026 milestones related to label expansion and development efforts, including completion of enrollment in a study in children aged zero to two years in the third quarter. Xu said the company has previously shared a target of approximately 72 children in that study, including sentinel open-label participants and blinded participants. Mikkelsen also said the company expects European approval by the end of 2026.

In addition, management discussed ongoing and planned work in other populations and regimens, including combination-therapy follow-up data in 2026 and plans to initiate work in adults with achondroplasia later in the year to assess meaningful benefits for daily life. Mikkelsen also said Ascendis intends to pursue additional indications, including hypochondroplasia, and highlighted the company’s broader aim of becoming a leading endocrine rare disease company.

Rare Pediatric Disease Priority Review Voucher

Ascendis also announced it was granted a Rare Pediatric Disease Priority Review Voucher (PRV) with the approval. Chief Financial Officer Rob Smith said the voucher status did not depend on approval timing because the company was “grandfathered in” based on a designation received years earlier. When asked about monetization, Smith said Ascendis is likely to sell the PRV, noting that many of the company’s products in development already receive priority reviews.

About Ascendis Pharma A/S NASDAQ: ASND

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.